Archive for the ‘Benzinga’ Category

Sarepta Could More Than Double Its Addressable Market In A Few Years, But Eteplirsen Isn’t The ‘Be All End All’

Courtesy of Benzinga.

Sarepta Could More Than Double Its Addressable Market In A Few Years, But Eteplirsen Isn't The 'Be All End All'

Sarepta Therapeutics Inc (NASDAQ: SRPT) announced the commencement of dosing in the Phase III ESSENCE study of SRP-4045 and SRP-4053.

“If the trial is successful, it could mean more than doubling of Sarepta’s addressable population in the next few years,” Baird’s Brian P. Skorney said in a report. He reiterated an Outperform rating on the company, with a price target of $102.

Related Link: Sarepta Dosing First Patients In Phase 3 Trial Of Duchenne Muscular Dystrophy Drug

The study would be testing two separate exon-skipping agents with the same backbone as eteplirsen in exon 45/53 amenable patients. ESSENCE is a placebo-controlled study lasting over 96 weeks and has potential to confirm the benefit provided by eteplirsen, Skorney mentioned.

Eteplirsen Not The ‘Be All’

“Now that the controversy of the last few years has come and gone, we want to emphasize that eteplirsen is not, and never has been, the “be all” for Sarepta,” Skorney commented. He stated that an eteplirsen approval on evidence of dystrophin production would be favorable for a class approval, and Sarepta is now a step closer to that potential outcome.

The analyst estimated a 50 percent chance of success on exons 45/53, with potential peak sales of more than $900 million in the US. He also estimated peak sales of Exondys 51 near $600 million.

Do you have ideas for articles/interviews you’d like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for SRPT

Date Firm Action From To
Sep 2016 RBC Capital Maintains Outperform
Sep 2016 Cowen & Co. Upgrades Market Perform Outperform
Sep 2016 Jefferies Upgrades Underperform Hold

View More Analyst Ratings for SRPT


View the Latest Analyst Ratings

Posted-In: Baird Brian P. SkorneyAnalyst Color Long Ideas Reiteration Top Stories Analyst Ratings Trading Ideas Best of Benzinga





7 Biggest Price Target Changes For Thursday

Courtesy of Benzinga.

  • Goldman Sachs lowered the price target for Lululemon Athletica inc. (NASDAQ: LULU) from $48 to $46. Lululemon shares fell 1.35 percent to $62.65 in pre-market trading.
  • Macquarie raised the price target for BlackBerry Ltd (NASDAQ: BBRY) from $7 to $8.50. BlackBerry shares declined 1.20 percent to $8.23 in pre-market trading.
  • Deutsche Bank increased the price target for eBay Inc (NASDAQ: EBAY) from $30 to $40. eBay shares rose 2.95 percent to $32.79 in pre-market trading.
  • Wunderlich raised the price target on Emerge Energy Services LP (NYSE: EMES) from $12 to $15. Emerge Energy shares gained 1.61 percent to $13.27 in pre-market trading.
  • Barclays lowered Great Plains Energy Incorporated (NYSE: GXP) price target from $31 to $29. Great Plains Energy shares gained 2.50 percent to close at $27.84 on Wednesday.
  • Deutsche Bank boosted Alibaba Group Holding Ltd (NYSE: BABA) price target from $109 to $138. Alibaba shares slipped 2.12 percent to $106.44 in pre-market trading.
  • Piper Jaffray lowered Intra-Cellular Therapies Inc (NASDAQ: ITCI) price target from $57 to $22. Intra-Cellular Therapies shares tumbled 65.34 percent to $14.68 in pre-market trading.

Latest Ratings for LULU

Date Firm Action From To
Sep 2016 Goldman Sachs Maintains Sell
Sep 2016 Susquehanna Initiates Coverage on Positive
Sep 2016 Jefferies Downgrades Buy Hold

View More Analyst Ratings for LULU


View the Latest Analyst Ratings

Posted-In: Price Target ChangesPrice Target Analyst Ratings





Akebia Price Target Lowered, Still A Buy At Brean

Courtesy of Benzinga.

Akebia Price Target Lowered, Still A Buy At Brean

Brean Capital assumes coverage of Akebia Therapeutics Inc (NASDAQ: AKBA) with a Buy rating, with a lowered target price of $18, citing potential success of its anemia drug.

The company’s lead product candidate, AKB-6548 or vadadustat is a small molecule oral drug being studied to treat anemia secondary to chronic kidney disease (CKD).

Akebia currently has two global Phase III trials underway, PRO2TECT and INNO2VATE, for non-dialysis (ND-CKD) and dialysis dependent (DD-CKD) respectively, with the enrollment completion expected in the former in 2H17 and readout in 2H18.

“We like Akebia’s asset, vadadustat, which is a new MOA for treating anemia. If successfully developed, it could change the standard of care,” analyst Difei Yang wrote in a note.

Related Link: Sarepta Dosing First Patients In Phase 3 Trial Of Duchenne Muscular Dystrophy Drug

“International partnerships aside, Akebia will commercialize vadadustat on its own in the US and we project sales to be around $515 mil in 2022, with sales for ND-CKD indication alone,” Yang continued.

The company has signed a deal with the MTPC for the development and commercialization of vadadustat in Japan and Asia and the company could sign a similar deal with respect to Europe in 2016.

Excluding MTPC deal, Akebia has cash and cash equivalents of about $189 million, which should be sufficient to fund the company’s operations through the second quarter of 2017.

Yang, who assumes 60 percent probability of success on PRO2TECT trials, lowered the target price to $18 from $26.

Shares of Akebia closed Wednesday’s regular trading session at $9.08. The revised price target implies potential upside of 98 percent.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you’d like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for AKBA

Date Firm Action From To
Sep 2016 Brean Capital Assumes Buy
Mar 2016 H.C. Wainwright Maintains Buy
Mar 2016 JMP Securities Maintains Market Outperform

View More Analyst Ratings for AKBA


View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Health Care Price Target Initiation Analyst Ratings Trading Ideas Best of Benzinga





Analysts React To Nike’s Q1 Results

Courtesy of Benzinga.

Analysts React To Nike's Q1 Results

Here is a compilation of the best reactions and insightful perspectives offered by sell-side analysts to Nike Inc (NYSE: NKE)’s mixed fiscal-first-quarter earnings report.

BofA Merrill Lynch: Neutral, Cuts 2017 EPS Estimate

Bank of America’s Neutral rating is premised on Nike losing market share in North America for the first time since 2010 as adidas AG (ADR) (OTC: ADDYY) and Under Armour Inc (NYSE: UA) make inroads.

The firm lowered its 2018 earnings per share estimate by $0.05 to $2.90, citing lower revenue outlook due to deceleration in future orders.

Goldman Sees North American Correction For Nike

Goldman Sachs said Nike is in the midst of a North American correction, strangulated by overheated wholesale orders, excess inventory and tougher competition.

Related Link: These Retailers Could Feel The Effects Of Nike’s Inventory Concerns

Reflecting subdued outlook for North America, Goldman lowered its earnings per share estimate for 2017 to $2.81 from $2.35, for 2018 to $2.51 from $2.67 and for 2019 to $2.88 from $3.02.

Canaccord On Sidelines, Stays At Hold

The firm maintains its Hold rating and a $52 price target on the shares of Nike, as it viewed the first quarter was peppered with red flags.

As Nike has to navigate an environment of changing consumer preferences it has not seen for years and this scenario is expected to linger for the foreseeable six to nine months, Canaccord believes the stock’s risk-reward have a downward bias.

Nike Appeases Bulls, Bears Alike –UBS

Despite futures growth rate looking low, UBS said the revenue growth rate over the next few quarters will improve as Nike laps shipments that were below the futures dollar levels reported last year.

UBS trimmed its price target to $67 from $70 but stays at Buy. The firm reduced its estimates for 2017 slightly on lower gross margins.

Jefferies Sees Near Term As Chaff But Long Term As Wheat

Jefferies said, with adidas breathing down its neck,…
continue reading





Expect A Big Day For Pepsi’s Stock

Courtesy of Benzinga.

Expect A Big Day For Pepsi's Stock

Morgan Stanley’s Dara Mohsenian believes PepsiCo, Inc. (NYSE: PEP) shares are likely to see a positive reaction following the company’s robust Q3 results and raised FY guidance.

Mohsenian maintained an Overweight rating on the company, with a $121 price target.

Related Link: Investors Cheer PepsiCo’s Q3 Results, Outlook

PepsiCo reported Q3 adjusted EPS of $1.40, well ahead of the consensus and estimate, driven by a 1 percent topline/gross profit beat, further supported by better than expected SG&A expense leverage, which led to a robust operating profit beat of 4 percent.

Below the line EPS was also helped by a lower than anticipated tax rate, while organic growth came in at a strong 4.2 percent, beating the consensus and the estimate.

“Core GM’s were up a solid +50 bps y-o-y, while SG&A was lower than expected as a percentage of sales, despite a 65 bps increase in A&M, driving a +3.7 percent operating profit beat vs consensus,” Mohsenian mentioned.

Listing PepsiCo among the top mega-cap picks, the analyst stated the robust Q3 results and raised guidance confirmed that the strong underlying results weren’t reflected in the stock’s valuation discount versus lower growth large cap CPG peers.

Guidance Raised

The company raised its core EPS guidance for FY16 from $4.71 to $4.78, slightly ahead of the consensus, since management now expects core constant currency EPS growth of 10 percent, with lower FX headwinds.

The FY organic sales growth guidance was left unchanged, as were other line items.

Do you have ideas for articles/interviews you’d like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for PEP

Date Firm Action From To
Sep 2016 Credit Suisse Initiates Coverage on Outperform
Jun 2016 Goldman Sachs Maintains Neutral
Apr 2016 Goldman Sachs Maintains Neutral

View More Analyst Ratings for PEP


View the Latest Analyst Ratings

Posted-In: Analyst Color Earnings Long Ideas News Guidance Reiteration Analyst Ratings Trading Ideas Best of Benzinga





Lululemon To Recuperate 15.5% Of Value, Vetr Crowd Believes

Courtesy of Benzinga.

Shares of Lululemon Athletica inc. (NASDAQ: LULU) have tumbled 21.75 percent in the past month. This, the Vetr crowd seems to believe, has unlocked some room for upside, as evidenced by its average price target of $71.40, which implies a potential return of 15.5 percent from current valuations.

Related Link: Here’s How Crowdsourced Ratings Can Beat The Market

Seeking to better reflect the larger upside potential, the Vetr community upgraded its rating on shares of Lululemon on Thursday, from 4.0 Stars (Buy) to 4.5 Stars (Strong Buy) – out of a possible 5 Stars rating.

It should be noted that, in accordance with the new score, 80 percent of the crowd’s ratings are bullish at the time.

Latest Ratings for LULU

Date Firm Action From To
Sep 2016 Goldman Sachs Maintains Sell
Sep 2016 Susquehanna Initiates Coverage on Positive
Sep 2016 Jefferies Downgrades Buy Hold

View More Analyst Ratings for LULU


View the Latest Analyst Ratings

Posted-In: VetrUpgrades Price Target Crowdsourcing Analyst Ratings General





15 Biggest Mid-Day Gainers For Thursday

Courtesy of Benzinga.


Catabasis Pharmaceuticals Inc (NASDAQ: CATB) shares jumped 59 percent to $7.13. Catabasis Pharmaceuticals and Sarepta Therapeutics Inc (NASDAQ: SRPT) reported a joint research collaboration in Duchenne Muscular Dystrophy.

Tabula Rasa HealthCare Inc (NASDAQ: TRHC) shares surged 26.5 percent to $15.18. Tabula Rasa priced IPO at $12 per share.

Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) shares climbed 19.7 percent to $2.98 as the company disclosed that its JUXTAPID capsules have been approved in Japan for the treatment of homozygous familial hypercholesterolemia.

Biostar Pharmaceuticals Inc (NASDAQ: BSPM) shares gained 18.5 percent to $4.10. Biostar Pharmaceuticals shares have dropped 31.35 percent over the past 52 weeks, while the S&P 500 index has gained 15.25 percent in the same period.

Mimecast Ltd (NASDAQ: MIME) shares surged 14 percent to $19.70. Mimecast priced secondary public offering of 4,000,000 shares at $16.50 per share.

Rex Energy Corporation (NASDAQ: REXX) gained 13 percent to $0.617. Stifel Nicolaus upgraded Rex Energy from Sell to Hold.

Pier 1 Imports Inc (NYSE: PIR) climbed 13.1 percent to $4.83. Pier 1 reported in-line loss for the second quarter, but revenue of $405.82 million, missed the Street’s consensus by $1.14 million. Its same store sales dropped 4.3 percent in the quarter.

Fulgent Genetics Inc (NASDAQ: FLGT) shares rose 9.8 percent to $9.88. Fulgent Genetics priced IPO at $9 per share.

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) gained 10.1 percent to $7.75. Amgen, Inc. (NASDAQ: AMGN) and…
continue reading





Low Expectations May Offer Tiffany A Chance To Shine

Courtesy of Benzinga.

CLSA sees multiple factors helping Tiffany & Co. (NYSE: TIF) to gain in the upcoming period though they wouldn’t be as glittering as the firm would have liked it to be. However, low expectations from the specialty retailer would make the stock to shine following a year and half of struggle with sales drop and tourist headwinds.

Analysts Rick Patel and Cait Howard initiated Tiffany with an Outperform rating and $80 price target.

One of the key factors that the brokerage expects is China as a growth driver in the immediate and long term. CLSA expects the specialty retailer to build its store base to 70 locations and that they could offer an incremental EPS addition of $0.95. The firm sees the region offering enough opportunities for future growth.

The second factor is the drop in input costs, which has the potential to expand gross margin until the year 2017. The lead analyst point out that the company was able to expand its margin for nearly two years despite sales drop. The company has the potential to gain from a mix perspective in the holiday season if it succeeds in higher pricing for new silver/gold initiatives.

Referring to product innovation, the brokerage said, “During the holidays, we expect an increase in silver jewelry SKUs (below US$500), combined with social-media marketing, will help it lure more millennial customers. Outperformance in this highly profitable category would further support GM expansion.”

CLSA expects Tiffany to continue to boost its dividend with the help of FCF and expects share repurchase to add 1–2 percent to EPS growth.

The stock traded at $72.49, gaining $1.28, or 1.80 percent.

Latest Ratings for TIF

Date Firm Action From To
Sep 2016 CLSA Initiates Coverage on Outperform
Aug 2016 Cowen & Company Maintains Market Perform
Aug 2016 Deutsche Bank Maintains Hold

View More Analyst Ratings for TIF


View the Latest Analyst Ratings

Posted-In: CLSAAnalyst Color Price Target Initiation Analyst Ratings





Shareholder’s Rights Agreements And What They’re Used For

Courtesy of Benzinga.

Shareholder's Rights Agreements And What They're Used For

Pier 1 Imports Inc (NYSE: PIR) announced earlier this week its board of directors approved a Shareholder Rights Protection Agreement.

This concept is fairly infrequent and uncommon. Simply put, a shareholders’ agreement details how current investors can make decisions regarding what outside parties become future shareholders.

The rights typically restrict any person or single from acquiring a position of 10 percent more of the company’s outstanding common stock.

The plan is usually put in place when the company feels it is under assault by an activist investor or a hostile takeover. If a person or group acquires more than 10 percent of a company, then shareholders will be able to buy shares at a discount which will dilute the total outstanding shares and make any takeover more difficult and expensive.

In Pier 1 Imports’ case, an activist investment firm, Alden Global Capital, bought a 9.5 percent stake in the retailer.

Related Link: Alden Issues Statement In Response To Pier 1 Imports’ Adoption Of A 10% Poison Pill

Here is how Pier 1 Imports described the agreement:

    “In general terms, the Rights restrict any person or group from acquiring beneficial ownership of 10 percent or more of the Company’s outstanding common stock (including, for these purposes, certain derivative securities) after the date of this announcement. The Rights will not prevent a takeover of the Company, but may cause substantial dilution to anyone acquiring 10 percent or more of the Company’s common stock, which may block or render more difficult a merger, tender offer or other business combination involving the Company that is not supported by the Board of Directors.”

Pier 1 Imports Chairman Terry London commented on the agreement as well, saying, “The board feels it is important to ensure that all shareholders have the opportunity to realize the long-term value of the iconic Pier 1 Imports brand, and to guard against coercive or unfair tactics to gain control of the Company without…
continue reading





Infant Tech Company Research Frontiers Could Grow Up To Be Worth $6 A Share

Courtesy of Benzinga.

Infant Tech Company Research Frontiers Could Grow Up To Be Worth $6 A Share

West Park Capital initiated coverage on Research Frontiers, Inc. (NASDAQ: REFR) with an Outperform rating and target price of $6.


Analyst Ishfaque Faruk cited the company’s licensing model, and its potential to generate earnings, specifically from the automotive sector, as its reason for the positive outlook.

Through its licensing model, Research Frontiers licenses out its proprietary technology to glass manufacturers in exchange for 5–15 percent of the licensee’s net sales.

Related Link: The Drone Wars Are Heating Up: Could GoPro Be Left in The Dust?

“We believe this to be an attractive business model, which will enable the company to generate significant earnings once it reaches critical mass,” stated Faruk.

According to Faruk, Research Frontiers’ technology has the most upside potential in automotive, which it expects to comprise about 67 percent of total revenues, with aircraft comprising 25 percent and museums, architectural and marine applications comprising.

At time of publication, Research Frontiers was seen trading at $2.60.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you’d like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for REFR

Date Firm Action From To
Sep 2016 WestPark Capital Initiates Coverage on Outperform

View More Analyst Ratings for REFR


View the Latest Analyst Ratings

Posted-In: Ishfaque Faruk West Park CapitalAnalyst Color Long Ideas Analyst Ratings Tech Trading Ideas





 
 
 

Zero Hedge

The Day Donald Trump Flunked Econ 101

Courtesy of ZeroHedge. View original post here.

By Chris at www.CapitalistExploits.at

Market dislocations occur when financial markets, operating under stressful conditions, experience large widespread asset mispricing.

Welcome to this week's edition of “World Out Of Whack” where every Wednesday we take time out of our day to laugh, poke fun at and present to you absurdity in global financial markets in all it's glorious insanity.

...

more from Tyler

Phil's Favorites

Beating Your Own Investments

Beating Your Own Investments

Courtesy of 

Add Julian Robertson and Howard Marks to the long list of billionaires that are less than optimistic about the future. All the reasons they cite are unfortunately very compelling, but pessimists always sound intelligent. You can probably count on one hand the number of investors that were actually able to capitalize on their pessimism.

But let’s say all these billionaires are right and U.S. stocks will in fact experience lower returns going forward. A good strategy would be to have your rate of investment outpace the return on your investment. As an example, let’s say you’ve saved some money and have $10,000 to invest. An...



more from Ilene

ValueWalk

Fear of Election Fraud Growing - 15 million registered voters may stay home, says new study

By JOHN F. BANZHAF. Originally published at ValueWalk.

Fear of Election Fraud Growing – Millions to Stay Home
Warnings by Banzhaf and Others of Election Hacking Affecting Voters

According to a new study, more than 15 million registered voters may not vote for president because of concerns about cyber hacking, with a majority believing that electronic voting machines involved in the presidential election could be hacked.

Election Fraud

Photo by Cea.

This dramatic change in attitude – since there have never been indications in previous elections of voting machines being tampered with – came about as a result of two recent demonstrations by professors about how...



more from ValueWalk

Market News

News You Can Use From Phil's Stock World

 

Financial Markets and Economy

Fed’s Lockhart Sees Potential for Raising Rates ‘Before Long’ (Bloomberg)

Federal Reserve Bank of Atlanta President Dennis Lockhart said the central bank is nearing its goals of maximum employment and steady inflation near 2 percent, leaving the economy primed for an increase in borrowing costs.

U.S. Economy Expanded at Revised 1.4% Rate in Second Quarter (Bloomberg) ...



more from Paul

Kimble Charting Solutions

Stocks and Crude Oil hung up by this key pattern!

Courtesy of Chris Kimble.

Below compares the price patterns of Crude Oil and the NYSE Index over the past 8-years. Crude and the NYSE don’t always correlate, over the past couple of years though, they have in a big way!

CLICK ON CHART TO ENLARGE

Since early 2015, the correlation between Crude Oil and the NYSE has been very high. They both hit highs together in 2015 at (1) and they both created double bottom lows together at (2).

Over the past 15-months, both appear to be ...



more from Kimble C.S.

Mapping The Market

The Industry That Was Crushed By The Obama Administration

By Jean-Luc

Good riddance – cleaned up a lot of frauds there:

The Industry That Was Crushed By The Obama Administration

In early 2009, the seven largest publicly traded college operators were worth a combined $51 billion. Today, they’ve been all but wiped out.

When Barack Obama took office, America’s seven largest publicly traded college operators were worth a combined $51 billion, with more than 815,000 students enrolled at campuses spread across the country. The schools were flooded with with people seeking shelter from the recession, returning to school to pick up new skills.

Almost eight years later, the industry has been decimated. The seven largest listed operators are worth just over $6 billion, and the most valuable co...



more from M.T.M.

Chart School

RTT browsing latest..

Courtesy of Read the Ticker.

Please review a collection of WWW browsing results.



Date Found: Saturday, 26 March 2016, 02:36:15 PM

Click for popup. Clear your browser cache if image is not showing.
Comment: ZH: Its a BULLARD market, the FED jaw boning is keeping the market up!



Date Found: Sunday, 27 March 2016, 02:31:30 PM

Click for popup. Clear your browser cache if image is not showing.
Comment: RTT: World trade near 2008/09 lows. SP500 near all time highs. PLACE YOUR BETS! Roll up! Roll up!



Date Found: Tuesday, 29 March 2016, 02:42:11 PM

Click for popup. Clear your browser cach...



more from Chart School

OpTrader

Swing trading portfolio - week of September 26th, 2016

Reminder: OpTrader is available to chat with Members, comments are found below each post.

 

This post is for all our live virtual trade ideas and daily comments. Please click on "comments" below to follow our live discussion. All of our current  trades are listed in the spreadsheet below, with entry price (1/2 in and All in), and exit prices (1/3 out, 2/3 out, and All out).

We also indicate our stop, which is most of the time the "5 day moving average". All trades, unless indicated, are front-month ATM options. 

Please feel free to participate in the discussion and ask any questions you might have about this virtual portfolio, by clicking on the "comments" link right below.

To learn more about the swing trading virtual portfolio (strategy, performance, FAQ, etc.), please click here ...



more from OpTrader

Members' Corner

Market Liquidity and Macroeconomic Bullshit

 

Market Liquidity and Macroeconomic Bullshit

Courtesy of The Nattering Naybob

STJL - "Apparently macroeconomics is all bullshit – ROFL! Paging Naybob now… Famous Economist Paul Romer Says Macroeconomics Is All Bullshit."

The Nattering One muses... Macroeconomics as practiced by academics and those in charge is pure voodoo. Better to chant over goat blood, bird feathers and scattered entrails...

As for reality, overnight CNH HIBOR (...



more from Our Members

Digital Currencies

Gold, Silver and Blockchain - Fintech Solutions To Negative Rates, Bail-ins, Currency Debasement and Cashless

Courtesy of ZeroHedge. View original post here.

By Jan Skoyles

I was so pleased yesterday by the announcement that I have joined the Research team at GoldCore as it meant that I could finally start talking about it and was back in a role that lets me indulge in my passion by researching and geeking out on all things gold, silver and money.

...



more from Bitcoin

Biotech

Epizyme - A Waiting Game

Reminder: Pharmboy is available to chat with Members, comments are found below each post.

Epizyme was founded in 2007, and trying to create drugs to treat patient's cancer by focusing on genetically-linked differences between normal and cancer cells. Cancer areas of focus include leukemia, Non-Hodgkin's lymphoma and breast cancer.  One of the Epizme cofounders, H. Robert Horvitz, won the Nobel Prize in Medicine in 2002 for "discoveries concerning genetic regulation of organ development and programmed cell death."

Before discussing the drug targets of Epizyme, understanding epigenetics is crucial to comprehend the company's goals.  

Genetic components are the DNA sequences that are 'inherited.'  Some of these genes are stronger than others in their expression (e.g., eye color).  Yet, some genes turn on or off due to external factors (environmental), and it is und...



more from Biotech

All About Trends

Mid-Day Update

Reminder: Harlan is available to chat with Members, comments are found below each post.

Click here for the full report.




To learn more, sign up for David's free newsletter and receive the free report from All About Trends - "How To Outperform 90% Of Wall Street With Just $500 A Week." Tell David PSW sent you. - Ilene...

more from David

Promotions

PSW is more than just stock talk!

 

We know you love coming here for our Stocks & Options education, strategy and trade ideas, and for Phil's daily commentary which you can't live without, but there's more!

PhilStockWorld.com features the most important and most interesting news items from around the web, all day, every day!

News: If you missed it, you can probably find it in our Market News section. We sift through piles of news so you don't have to.   

If you are looking for non-mainstream, provocatively-narrated news and opinion pieces which promise to make you think -- we feature Zero Hedge, ...



more from Promotions



FeedTheBull - Top Stock market and Finance Sites



About Phil:

Philip R. Davis is a founder Phil's Stock World, a stock and options trading site that teaches the art of options trading to newcomers and devises advanced strategies for expert traders...

Learn more About Phil >>


As Seen On:




About Ilene:

Ilene is editor and affiliate program coordinator for PSW. She manages the site market shadows, archives, more. Contact Ilene to learn about our affiliate and content sharing programs.

Market Shadows >>